Why are black men missing from prostate cancer research?

November 24, 2016

Black men are three times more likely to develop prostate cancer than other demographics, yet black men are consistently underrepresented in research studies, say researchers from King's College London in a new paper published in ecancermedicalscience.

The problem? Healthcare research conducted in one demographic often doesn't translate to results for other demographics, and recruitment of ethnic minorities often fails to meet a balance.

For example, in 2015, researchers realised that the HPV vaccines being given in the United States of America were less effective in African American women. The vaccines were developed for strains of the virus more commonly found in white women, on whom the clinical trials had been based.

Now, researchers warn that black men may not benefit from current research studies on prostate cancer.

"It's important that future research be generalizable," says study author Dr Mieke Van Hemelrijck of King's College London, London, UK. She explains that if black men don't participate in research studies, their unique needs and experiences will be missing from the conclusions.

To find out why this community is less likely to participate in research recruitment, the researchers surveyed the opinions and attitudes of sixteen black men undergoing treatment for prostate cancer in London.

"We uncovered a number of barriers to the recruitment of black men with prostate cancer into research studies," says Dr Van Hemelrijck.

These include mistrust of researchers and their motives, lack of understanding about the benefits and consequences of participating, and even a feeling in immigrant communities that traditional medicines and coping methods are more reliable.

So how can research studies on prostate cancer become more inclusive for black men?

The researchers suggest that community-driven engagement may be the way forward, as well as dissemination of reliable information.

Hearing from black male survivors of prostate cancer may improve screening uptake as well as participation in research.

"There was mention of a mechanic who offered a free MOT to every black man who had received a prostate check at their GP surgery," says lead author Dr Charlotte Toms of King's College London, London, UK.

"When asked "do you think it helps the fact that he was a black man, who had been through it himself? And then he was then trying to engage people to come in?" An individual responded, "yes, yes. That helped.""
-end-
Read the article here: http://ecancer.org/journal/10/695-research-engagement-among-black-men-with-prostate-cancer.php

ecancermedicalscience

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.